Correlation Between Achilles Therapeutics and Lipella Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Achilles Therapeutics and Lipella Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Achilles Therapeutics and Lipella Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Achilles Therapeutics PLC and Lipella Pharmaceuticals Common, you can compare the effects of market volatilities on Achilles Therapeutics and Lipella Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Achilles Therapeutics with a short position of Lipella Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Achilles Therapeutics and Lipella Pharmaceuticals.

Diversification Opportunities for Achilles Therapeutics and Lipella Pharmaceuticals

-0.26

Correlation Coefficient

Achilles Therapeutics  Lipella Pharmaceuticals

Very good diversification

The 3 months correlation between Achilles and Lipella is -0.26. Overlapping area represents the amount of risk that can be diversified away by holding Achilles Therapeutics PLC and Lipella Pharmaceuticals Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Lipella Pharmaceuticals and Achilles Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Achilles Therapeutics PLC are associated (or correlated) with Lipella Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Lipella Pharmaceuticals has no effect on the direction of Achilles Therapeutics i.e., Achilles Therapeutics and Lipella Pharmaceuticals go up and down completely randomly.

Pair Corralation between Achilles Therapeutics and Lipella Pharmaceuticals

Given the investment horizon of 90 days Achilles Therapeutics PLC is expected to generate 0.57 times more return on investment than Lipella Pharmaceuticals. However, Achilles Therapeutics PLC is 1.75 times less risky than Lipella Pharmaceuticals. It trades about 0.16 of its potential returns per unit of risk. Lipella Pharmaceuticals Common is currently generating about 0.02 per unit of risk. If you would invest  71.00  in Achilles Therapeutics PLC on September 3, 2024 and sell it today you would earn a total of  37.00  from holding Achilles Therapeutics PLC or generate 52.11% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Achilles Therapeutics PLC  vs.  Lipella Pharmaceuticals Common

Achilles Therapeutics PLC

Risk-Adjusted Performance

12 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Achilles Therapeutics PLC are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. Despite quite weak technical indicators, Achilles Therapeutics disclosed solid returns over the last few months and may actually be approaching a breakup point.

Lipella Pharmaceuticals

Risk-Adjusted Performance

1 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Lipella Pharmaceuticals Common are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of very inconsistent basic indicators, Lipella Pharmaceuticals may actually be approaching a critical reversion point that can send shares even higher in January 2025.

Pair Trading with Achilles Therapeutics and Lipella Pharmaceuticals

The main advantage of trading using opposite Achilles Therapeutics and Lipella Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Achilles Therapeutics position performs unexpectedly, Lipella Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lipella Pharmaceuticals will offset losses from the drop in Lipella Pharmaceuticals' long position.

The idea behind Achilles Therapeutics PLC and Lipella Pharmaceuticals Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.